Close this search box.

Mogrifiy completes Series A financing round

Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.

The financing was led by Parkwalk Advisors and co-financed by Astellas Venture Management as well as 24Haymarket, co-Founder of Abcam PLC, Dr Jonathan Milner, and Mogrify CEO, Dr Darrin M Disley OBE. The company said it will use the proceeds to support the development of its preclinical immuno-oncology and ophthalmology programs, as well as to advance its platform for direct stem cell reprogramming.

Mogrify aims at using allogeneic cell therapies to treat blood cancers and solid tumours, and wants to develop  in vivo reprogramming therapies targeting retinal degeneration, a leading cause of blindness.

Mogrify’s direct cellular reprogramming platform leverages transcriptomic data to identify optimal combinations of transcription factors for the conversion, via enhanced forward reprogramming or transdifferentiation, of any cell type into any other cell type.

Upon the financing, Mogrify  announced the appointments of Dr Lorenz Mayr, former CTO of GE Healthcare Life Sciences and Vice President Discovery Sciences at AstraZeneca, as Non-Executive Director, after serving as an Observer since July 2020, and Dr Hiromichi Kimura, Astellas Venture Management as an Observer.